EYSZ
Piedmont
About EYSZ
Eysz is developing a digital health platform that measures disease progression, intervention efficacy and side effects to assist clinicians in developing a personalized care plan for neurological diseases. Doctors currently rely on patient self-reported data and subjective clinical exams to manage and treat chronic neurological disorders. The lack of a reliable biomarker in neurological disease leads to economic burdens of $1.7T in the US and Europe alone and stagnant patient outcomes with no significant improvement in outcomes in the last 30 years. Eysz is using analysis of eye-movements as a biomarker to assess brain health across neurological disorders starting with epilepsy – a disorder characterized by recurrent seizures. After completing a successful clinical study sponsored by the NIH and NSF Eysz will be releasing their first product to diagnose and monitor childhood absence epilepsy in Q3 2023.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2025)
- Website: eyszlab.com
Industries & Categories
Health Care, Information Technology, Machine Learning, Software
Social Profiles
Canonical: https://fsome.com/organization/eysz-107069 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.